APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes (APPRAISE)

February 19, 2026 updated by: University of California, San Francisco
The study will evaluate whether atropine eyedrops are beneficial when used after certain eye surgeries.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Atropine eyedrops are often used after certain eye surgeries. This study will compare several outcomes following surgery in patients either using or not using this treatment.

Study Type

Interventional

Enrollment (Estimated)

62

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94143
        • Recruiting
        • University of California, San Francisco
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • patient undergoing vitrectomy surgery
  • able to give informed consent

Exclusion Criteria:

  • post-operative eyedrop regimens that include topical non steroidal anti-inflammatory medications
  • subjects with altered post-operative eyedrop schedule for enhanced inflammation control
  • documented allergy to atropine

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
No atropine
Experimental: Experimental
Participant uses atropine eyedrops
Drug: Atropine 1%
Subtraction of atropine eyedrops from post-operative treatment regimen
Other Names:
  • Atropine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain score on the Visual Analog Scale (VAS)
Time Frame: 1 month
Whether atropine use impacts post-operative pain score on the standard Visual Analog Scale (VAS)
1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anterior chamber inflammation (aqueous cell and flare)
Time Frame: 1 month
Whether atropine impacts the occurrence of post-operative inflammation, quantified as aqueous cell and flare, using the Standardization of Uveitis Nomenclature (SUN) Criteria
1 month
Cystoid macular edema detected by optical coherence tomography
Time Frame: 1 month
Whether atropine impacts the occurrence of cystoid macular edema after surgery, detected by optical coherence tomography scanning of the retina
1 month
Time to visual recovery
Time Frame: 1 month
Whether atropine impacts the time to visual recovery
1 month
Intraocular pressure
Time Frame: 1 month
Whether atropine impacts intraocular pressure after surgery
1 month
Posterior synechiae formation
Time Frame: 1 month
Presence or absence of posterior synechiae assessed by slit lamp examination at post-operative visits
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, San Francisco

Investigators

  • Principal Investigator: Jay Stewart, MD, University of California, San Francisco

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2026

Primary Completion (Estimated)

February 1, 2028

Study Completion (Estimated)

February 1, 2029

Study Registration Dates

First Submitted

February 5, 2026

First Submitted That Met QC Criteria

February 19, 2026

First Posted (Actual)

February 25, 2026

Study Record Updates

Last Update Posted (Actual)

February 25, 2026

Last Update Submitted That Met QC Criteria

February 19, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 25-45406

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Eye Disorders

Clinical Trials on Atropine 1%

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe